Common use of Sales Milestone Payments Clause in Contracts

Sales Milestone Payments. With respect to each of the First Antibody and the Subsequent Antibody, Pieris shall pay the following sales milestone payments to Enumeral by the later of (i) [***] days of the occurrence of [***] and [***] Product to achieve each of the following events and (ii) [***] days of the occurrence of the following events for any corresponding milestone payment with respect to any payment from Sublicensee to Pieris: Net sales threshold [***] Product [***] Product 1st year with Net Sales [***] [***] [***] 1st year with Net Sales [***] [***] [***] 1st year with Net Sales [***] [***] [***] Total [***] [***] Grand Total $67,500,000 (sixty seven million five hundred thousand dollars) For avoidance of any doubt, in no event shall milestone payments paid by Pieris under this Section 4.4 exceed $67,500,000 (sixty-seven million five hundred thousand dollars) for the First Antibody and $67,500,000 (sixty-seven million five hundred thousand dollars) for the Subsequent Antibody. Net Sales shall be calculated on a worldwide basis.

Sales Milestone Payments. With respect to each of the First Antibody and the Subsequent Antibody, Pieris shall pay the following sales milestone payments to Enumeral by the later of (i) [***] * days of the occurrence of [***] and [***] * Product to achieve each of the following events and (ii) [***] * days of the occurrence of the following events for any corresponding milestone payment with respect to any payment from Sublicensee to Pieris: Net sales threshold [***] * Product [***] * Product 1st year with Net Sales [***] [***] [***] * * * 1st year with Net Sales [***] [***] [***] * * * 1st year with Net Sales [***] [***] [***] * * * Total [***] [***] * * Grand Total $67,500,000 (sixty seven million five hundred thousand dollars) For avoidance of any doubt, in no event shall milestone payments paid by Pieris under this Section 4.4 exceed $67,500,000 (sixty-seven million five hundred thousand dollars) for the First Antibody and $67,500,000 (sixty-seven million five hundred thousand dollars) for the Subsequent Antibody. Net Sales shall be calculated on a worldwide basis.

Sales Milestone Payments. With respect to each of the First Antibody and the Subsequent Antibody, Pieris shall pay the following sales milestone payments to Enumeral by the later of (i) [***] * days of the occurrence of [***] and [***] * Product to achieve each of the following events and (ii) [***] * days of the occurrence of the following events for any corresponding milestone payment with respect to any payment from Sublicensee to Pieris: Net sales threshold [***] * Product [***] * Product 1st year with Net Sales [***] [***] [***] * * * 1st year with Net Sales [***] [***] [***] * * * 1st year with Net Sales [***] [***] [***] * * * Total [***] [***] * * Grand Total $67,500,000 (sixty seven million five hundred thousand dollars) For avoidance of any doubt, in In no event shall milestone payments paid by Pieris under this Section 4.4 exceed $67,500,000 (sixty-seven million five hundred thousand dollars) for the First Antibody and $67,500,000 (sixty-seven million five hundred thousand dollars) for the Subsequent Antibody. Net Sales shall be calculated on a worldwide basis.

Sales Milestone Payments. With respect to each of the First Antibody and the Subsequent Antibody, Pieris shall pay the following sales milestone payments to Enumeral by the later of of (i) [***] days of the occurrence of [***] and [***] Product to achieve each of the following events and (ii) [***] days of the occurrence of the following events for any corresponding milestone payment with respect to any payment from Sublicensee to Pieris: Net sales threshold [***] Product [***] Product 1st year with Net Sales [***] [***] [***] 1st year with Net Sales [***] [***] [***] 1st year with Net Sales [***] [***] [***] Total [***] [***] Grand Total $67,500,000 (sixty seven million five hundred thousand dollars) For avoidance of any doubt, in In no event shall milestone payments paid by Pieris under this Section 4.4 exceed $67,500,000 (sixty-seven million five hundred thousand dollars) for the First Antibody and $67,500,000 (sixty-seven million five hundred thousand dollars) for the Subsequent Antibody. Net Sales shall be calculated on a worldwide basis.